Research: VENNOS and COLLEAGUES,

Listed in Issue 221

Abstract

VENNOS and COLLEAGUES, Scientific Medical Division, Padma Inc., Hinwil, Switzerland provided an overview of the clinical studies on the efficacy and safety of Padma 28, complex Tibetan medical herbal formulation.

Background

Padma 28 is an herbal formula from Tibetan Medicine, which since 35 years has been registered in Switzerland as a drug for the symptoms of circulatory disorders. Over this time, a large body of scientific literature has accumulated. The aim of this article was to give an overview of the clinical studies.

Methodology

A systematic literature search was done in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CCRCT). The clinical trials found were assessed regarding fields of application, efficacy, and safety, as well as methodological quality and level of evidence.

Results

29 trials (1 meta-analysis, 21 controlled trials, 7 open trials) and 3 retrospective case studies were found. They deal with different indications and include a total of 1,704 verum (of these, 697 children), 333 placebo, and 394 untreated or healthy patients. Dropouts and withdrawals were 2.5 and 3.5 times higher in the placebo than in the verum group, respectively. The highest level of evidence for the use of Padma 28 was found in the indication of intermittent claudication (11 trials). Indications of efficacy were also found in other vascular (6 trials) and different inflammatory diseases (12 trials).

Conclusion

The results suggest a favourable safety profile for Padma 28, also in the children examined (41% of the study population). Furthermore, the results show a broad field of applications. According to clinical evidence, Padma 28 has shown to be a safe and effective symptomatic treatment option for atherosclerosis-related diseases such as intermittent claudication. It also seems to have a potential for application in certain chronic inflammatory diseases such as recurrent respiratory tract infections, viral hepatitis, and multiple sclerosis. However, further randomized controlled trials (RCT) are needed to confirm these findings.

References

Vennos C, Melzer J and Saller R. Clinical studies on the efficacy and safety of Padma 28, a complex herbal formulation from Tibetan medicine: an overview. Forsch Komplementmed. 20 Suppl 2:25-30. doi: 10.1159/000351722. Epub 2013 Jun 21. 2013.

Comment

This is an important literature search, showing that Padma 28 to be safe and effective for atherosclerosis-related conditions including intermittent claudication; we look forward to further research and RCTs to confirm initial findings.

ICAN Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

Cycle from Milan to Venice for Regain 2023

top of the page